Avalon GloboCare Corp (NASDAQ:ALBT) saw its stock jump 16% following the announcement that it has been granted a standard patent in Hong Kong for its proprietary CAR-T and CAR-Natural Killer (CAR-NK) cell technology.
The newly issued Certificate of Invention—Patent No. HK40074322—was awarded by the Hong Kong Intellectual Property Department and is based on a previously secured Chinese patent. The protection, retroactive to February 21, 2020, extends for 20 years and reinforces Avalon’s commitment to advancing its intellectual property portfolio in Asia.
Developed in partnership with Hong Kong-based biotech firm Arbele Limited, the patented innovations are designed to enhance the effectiveness of CAR-T and CAR-NK therapies. Notably, the technology incorporates a bispecific Anti-CD19xCD22 CAR framework to target multiple cancer antigens, helping to prevent tumor escape, along with localized cytokine release to stimulate immune activity directly at tumor sites.
“Securing this patent in Hong Kong marks an important expansion of our global intellectual property portfolio and reinforces our competitive positioning in the rapidly advancing field of cell-based immunotherapy,” said David Jin, M.D., Ph.D., Avalon’s CEO.
The Hong Kong patent adds to Avalon’s growing suite of international protections, complementing existing patents filed under the Patent Cooperation Treaty and bolstering its standing in the global cell therapy landscape.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.